CBD and Methotrexate

Plain-language summary

Methotrexate (MTX) is a widely used drug for rheumatoid arthritis, psoriasis, inflammatory bowel disease, and certain cancers. It has a narrow therapeutic window — the dose that helps is close to the dose that harms the liver, bone marrow, or kidneys ^[1].

CBD (cannabidiol) is a non-intoxicating cannabinoid sold as a prescription drug (Epidiolex/Epidyolex) and as a largely unregulated supplement. CBD is known to inhibit several liver enzymes (CYP3A4, CYP2C9, CYP2C19, CYP1A2) and drug transporters (P-glycoprotein, BCRP) that methotrexate depends on for clearance ^[2][3][4].

The combination is not automatically dangerous, but it is not a neutral pairing either. Animal work shows CBD raises MTX blood levels ^[5]. Human controlled data is essentially absent. The prudent stance is: disclose CBD use to your rheumatologist or oncologist before starting, and don't assume 'natural' means 'safe with chemo.'

This is not medical advice. It is a summary of published evidence. Decisions about methotrexate dosing, or whether to use CBD alongside it, belong to you and your prescriber.

What probably works (strong or moderate evidence)

Honestly, in this specific pairing: nothing yet meets a 'probably works' bar in humans.

What is well-supported is the mechanism of interaction, not a clinical benefit:

• CBD inhibits CYP3A4 and CYP2C enzymes in vitro and in humans at therapeutic doses ^[2][3]. Strong evidence
• CBD inhibits BCRP and P-glycoprotein, transporters that move MTX out of cells and into bile/urine ^[4]. Strong evidence
• Methotrexate is a known BCRP substrate; inhibiting BCRP raises MTX exposure in animal models ^[5][6]. Strong evidence

So the interaction is real. What is not established is that combining them produces any therapeutic benefit beyond MTX alone.

What might work (weak or preliminary evidence)

• CBD as an adjunct for MTX-related nausea. Cannabinoids (mostly THC/nabilone, not CBD) have evidence for chemotherapy-induced nausea, but MTX at rheumatologic doses causes nausea through different mechanisms, and CBD monotherapy for nausea has thin data ^[7]. Weak / limited
• CBD for pain in rheumatoid arthritis or psoriatic arthritis alongside MTX. Small surveys and one observational study suggest patients report benefit, but there are no controlled trials of CBD in RA specifically ^[8]. Weak / limited
• Reduced MTX dose because CBD raises levels. Mechanistically plausible from animal data ^[5], but no human dosing study has tested this. Do not self-adjust. Weak / limited

What doesn't work / weak evidence

• 'CBD protects the liver from methotrexate.' This is a popular claim in wellness marketing. Some rodent studies show CBD reduces MTX-induced liver injury markers ^[9], but CBD itself has caused transaminase elevations in humans in the Epidiolex trials ^[10]. Stacking two hepatotoxic-capable agents to 'protect' the liver is not supported. Disputed
• 'CBD boosts methotrexate's anticancer effect.' Preclinical cell-line work exists for cannabinoids and cancer generally, but there is no human trial showing CBD improves MTX outcomes in leukemia, lymphoma, or any oncology indication. No data
• 'CBD is safe because it's natural / non-intoxicating.' CBD has a real drug-interaction profile documented by the FDA and EMA ^[10][11]. Strong evidence (against the folklore)
• Indica vs. sativa guidance for autoimmune patients. This is marketing folklore, not pharmacology. No data

What we don't know

• The magnitude of the CBD–MTX interaction in humans at typical supplement doses (10–50 mg/day) versus Epidiolex doses (up to 20 mg/kg/day). Most interaction data is at the high end.
• Whether the interaction matters at low-dose weekly MTX (7.5–25 mg/week for RA) the same way it might at high-dose MTX (grams/m² in oncology).
• Whether full-spectrum hemp products (containing minor cannabinoids, terpenes, and trace THC) behave differently than isolated CBD.
• Long-term hepatic safety of combined use.
• Whether CBD affects MTX polyglutamation inside cells (the form responsible for its therapeutic effect).

Comparison with standard supportive care

Standard tools for MTX tolerability are well-defined and have real trial data:

• Folic or folinic acid supplementation reduces MTX GI side effects and transaminitis in RA. Strong evidence ^[12]. Strong evidence
• Split dosing or switching to subcutaneous MTX reduces nausea and improves bioavailability. Moderate evidence ^[13]. Strong evidence
• Ondansetron or metoclopramide for acute MTX nausea. Standard of care.
• Dose titration and lab monitoring (CBC, LFTs, creatinine) every 1–3 months.

CBD does not have evidence at this level for any MTX-related indication. If the goal is to tolerate MTX better, the interventions above are the ones with data. See Methotrexate Supportive Care and CBD Drug Interactions.

Risks and practical considerations

Higher-concern scenarios:

• High-dose CBD (>300 mg/day, or Epidiolex-range dosing).
• Oncology-dose MTX (much higher plasma levels, tighter margin).
• Pre-existing liver disease, alcohol use, or other hepatotoxic drugs (leflunomide, isoniazid, azole antifungals).
• Impaired renal function — MTX clearance is primarily renal, and delayed clearance is the main driver of MTX toxicity.
• Concurrent NSAIDs, PPIs, trimethoprim, or probenecid, which independently raise MTX levels.

Signs of MTX toxicity to watch for: mouth ulcers, unusual bruising or bleeding, persistent nausea, dark urine, jaundice, dry cough or shortness of breath, fever, or a drop in blood counts. These require urgent contact with your prescriber regardless of CBD use.

Practical steps if you use both:

1. Tell your prescriber the product, dose, and frequency of CBD. Bring the label.
2. Expect closer LFT and CBC monitoring, at least initially.
3. Avoid starting CBD in the same month you start or dose-escalate MTX — you won't know which drug caused a lab change.
4. Prefer products with a certificate of analysis (COA) from a third-party lab. Unregulated CBD products have shown large label inaccuracies ^[14].

This is not medical advice. Talk to the clinician who prescribed your methotrexate before starting, stopping, or changing CBD.

Sources

How this page was made

Related

• Cannabis and Rheumatoid Arthritis — What the evidence actually says about using cannabis, THC, and CBD for rheumatoid arthriti...